drug discovery

Delta4

Identify new therapeutic indications for existing compounds using an AI-powered systems biology platform to reduce R&D costs and accelerate time-to-market.

Delta4 screenshot

About Delta4

Delta4 is a specialized TechBio company that leverages artificial intelligence and systems biology to revolutionize the drug discovery process. Its primary mission is to help pharmaceutical and biotechnology companies expand the indications for drugs that already possess established safety profiles. By focusing on drug repurposing and indication expansion, the platform enables organizations to bypass many of the initial risks associated with early-stage drug development, significantly shortening the timeline for bringing new treatments to patients. This approach focuses on efficiency and safety by building upon clinical data that has already been verified in human subjects. At the core of Delta4’s offering is Hyper-C, a proprietary AI-powered software platform. This technology integrates large-scale biological data with computational modeling to simulate and predict drug behavior in silico. The platform is operated by a dedicated team of computational biologists who analyze complex disease mechanisms and detect previously undetected relationships between known drugs and potential new therapeutic targets. This data-driven approach allows for high precision and speed in uncovering new opportunities that traditional lab-based methods might overlook, making it possible to identify potential treatments for complex conditions like Long COVID. The service is specifically designed for R&D teams in the pharmaceutical industry, academic research institutions, and biotech startups. By providing detailed in-silico models and predictive insights, Delta4 helps these stakeholders reduce the high costs and failure rates typically associated with clinical trials. The tool is particularly effective for organizations looking to breathe new life into existing assets or those focused on specialized areas where understanding intricate biological networks is crucial for therapeutic success. What distinguishes Delta4 from generic AI discovery tools is its deep integration of systems biology with human expertise. Unlike purely automated solutions, Delta4 emphasizes a collaborative process where AI-generated insights are refined by subject matter experts. Furthermore, its membership in frameworks like Scientist.com ensures a streamlined and transparent collaboration process, making it a reliable partner for global pharmaceutical giants and top-tier medical universities. The company maintains an active presence in the scientific community, regularly publishing research on Proof of Concept clinical trials and innovative drug development strategies.

Delta4 pros & cons

Pros

  • Focuses on drugs with known safety profiles to significantly reduce clinical risk.
  • Proprietary Hyper-C platform offers high-speed computational modeling and precision.
  • Established partnerships with major industry players like Takeda and Biogen.
  • Streamlined procurement and legal transparency through Scientist.com membership.
  • Combines automated AI processing with human-expert computational biology analysis.

Cons

  • Pricing is not publicly disclosed and requires a custom quote via direct contact.
  • The tool is specialized for existing drug expansion rather than de novo molecule design.
  • Highly technical data outputs require specialized biological knowledge to interpret.

Delta4 use cases

  • Pharmaceutical R&D heads can use Hyper-C to identify new therapeutic uses for existing compounds, maximizing the ROI of their current asset portfolio.
  • Biotech startups can leverage in-silico modeling to validate potential drug targets before committing to expensive and risky physical clinical trials.
  • Academic researchers can partner with the computational biology team to map complex disease mechanisms for conditions like Long COVID.
  • Clinical trial managers can utilize predictive data to design more focused and safer Proof of Concept (PoC) studies.
  • Therapeutic developers can use the platform to identify undetected relationships between known safety-profile drugs and rare disease indications.

Delta4 features

  • scientist.com collaboration framework
  • computational biology expert consultation
  • large-scale biological data analysis
  • disease mechanism mapping
  • drug indication expansion identification
  • systems biology computational modeling
  • in-silico drug behavior prediction
  • hyper-c ai software platform

Delta4 FAQs

What is the primary focus of Delta4's technology?

Delta4 focuses on indication expansion, using its Hyper-C platform to find new therapeutic uses for existing drugs with known safety profiles. This reduces the time and risk associated with traditional drug development.

What is the Hyper-C platform?

Hyper-C is a proprietary AI-powered software platform that combines systems biology and computational modeling to predict drug behavior in silico. It allows researchers to detect relationships between drugs and diseases with high accuracy.

How does Delta4 ensure the quality of its AI-driven insights?

The Hyper-C platform is operated by a team of highly skilled computational biologists. They manually analyze the data outputs to produce unique insights and validate drug indication expansion opportunities.

Does Delta4 offer partnership opportunities?

Yes, Delta4 offers collaborations on research, co-development, and consortia projects. They work with pharmaceutical companies, biotech firms, and academic institutions globally.

How does Delta4 streamline the procurement process for its services?

Delta4 is a member of Scientist.com, which provides a platform for streamlining transparency and cooperation. This framework simplifies the process of defining terms and conditions for agreements.

Can Delta4 assist with Proof of Concept (PoC) clinical trials?

The platform provides predictive data and in-silico models that help inform and accelerate early Phase II clinical studies. This helps researchers answer fundamental questions about drug efficacy before full-scale trials.

Open roles

All AI jobs

EU-funded computational biology PhD position (Prostate Research)

Education Requirements:

  • PhD candidate

Other Requirements:

  • EU-funded

Responsibilities:

  • Prostate Research

  • Computational biology

Show more details

EU-funded computational biology PhD position (Kidney Research)

Education Requirements:

  • PhD candidate

Other Requirements:

  • EU-funded

Responsibilities:

  • Kidney Research

  • Computational biology

Show more details

Ratings & reviews

No reviews yet. Be the first to share how Delta4 worked for you.